Sanofi licences Trovax from Oxford BioMedica
Oxford BioMedica and sanofi-aventis have agreed a licensing deal over TroVax for the treatment and prevention of cancers.
Oxford BioMedica and sanofi-aventis have agreed a licensing deal over TroVax for the treatment and prevention of cancers.
TroVax is Oxford BioMedica's lead cancer immunotherapy. It has been evaluated in clinical trials involving more than 180 patients with various forms of cancer. A Phase III trial in renal cancer is ongoing.
Sanofi-aventis will pay Oxford BioMedica up to Euro 518 m (US$690 m) if all development and registration targets are met for certain defined indications. Additional payments will be made if regulatory milestones are achieved in other cancer types.
Oxford BioMedica will receive an initial payment of €29 m (US$39 m) and further near-term payments of €19 m (US$25 m) as milestones linked to the ongoing Phase III TRIST study in renal cancer.
The company will also get royalties on global sales of TroVax and commercial milestones when net sales of TroVax reach certain levels. It has an option to develop TroVax for other cancer types in exchange for enhanced financial returns, and sanofi-aventis will keep all commercial rights.
Oxford BioMedica will supply TroVax to sanofi-aventis on commercial terms. Both companies will co-fund the ongoing Phase III TRIST study of TroVax in renal cancer. Sanofi-aventis will fund all future r&d and implementation of a development plan for TroVax in metastatic colorectal cancer.